Advertisement

Seminars in Immunopathology

, Volume 41, Issue 1, pp 69–85 | Cite as

Therapeutic cancer vaccine: building the future from lessons of the past

  • T. Tran
  • C. Blanc
  • C. Granier
  • A. Saldmann
  • C. Tanchot
  • Eric Tartour
Review

Abstract

Anti-cancer vaccines have raised many hopes from the start of immunotherapy but have not yet been clinically successful. The few positive results of anti-cancer vaccines have been observed in clinical situations of low tumor burden or preneoplastic lesions. Several new concepts and new results reposition this therapeutic approach in the field of immunotherapy. Indeed, cancers that respond to anti-PD-1/PD-L1 (20–30%) are those that are infiltrated by anti-tumor T cells with an inflammatory infiltrate. However, 70% of cancers do not appear to have an anti-tumor immune reaction in the tumor microenvironment. To induce this anti-tumor immunity, therapeutic combinations between vaccines and anti-PD-1/PD-L1 are being evaluated. In addition, the identification of neoepitopes against which the immune system is less tolerated is giving rise to a new enthusiasm by the first clinical results of the vaccine including these neoepitopes in humans. The ability of anti-cancer vaccines to induce a population of anti-tumor T cells called memory resident T cells that play an important role in immunosurveillance is also a new criterion to consider in the design of therapeutic vaccines.

Keywords

Cancer vaccine Checkpoint inhibitor Tumor antigens CD8+ T cells Resident memory T cells Therapeutic combination 

Notes

Acknowledgements

This work has been funded by Institut National du Cancer (INCa), PL-Bio 2016 (ET), Labex Immuno-oncology, CARPEM (SIRIC), and ANR Selectimmuno. CG is a recipient of a fellowship Carpem and AS a recipient of Fondation Foncer.

References

  1. 1.
    P van der Bruggen, C Traversari, P Chomez, C Lurquin, E De Plaen, B Van den Eynde, A Knuth, T Boon (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254Google Scholar
  2. 2.
    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363. 2010/09/08 edn. doi:  https://doi.org/10.1056/NEJMoa1001294
  3. 3.
    Maeng H, Terabe M, Berzofsky JA (2018) Cancer vaccines: translation from mice to human clinical trials. Curr Opin Immunol 51. 2018/03/20 edn.  https://doi.org/10.1016/j.coi.2018.03.001
  4. 4.
    Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14. 2014/01/25 edn.  https://doi.org/10.1038/nrc3670
  5. 5.
    Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176. 1992/11/01 ednGoogle Scholar
  6. 6.
    P Combe, E de Guillebon, C Thibault, C Granier, E Tartour, S Oudard (2015) Trial watch: therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology 4.  https://doi.org/10.1080/2162402X.2014.1001236
  7. 7.
    Martin M, Lopez-Tarruella S (2016) Emerging therapeutic options for HER2-positive breast Cancer. American Society of Clinical Oncology educational book American Society of Clinical Oncology. Meeting 35. 2016/06/02 edn.  https://doi.org/10.14694/EDBK_159167
  8. 8.
    Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA (2017) Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and Trastuzumab in breast Cancer patients. Ann Surg Oncol 24. 2017/03/21 edn.  https://doi.org/10.1245/s10434-017-5844-0
  9. 9.
    Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer J Clin Oncol 27. 2009/09/02 edn.  https://doi.org/10.1200/JCO2008.20.6789
  10. 10.
    MJ Scanlan, AJ Simpson, LJ Old (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4 11. Fiszer D, Kurpisz M (1998) Major histocompatibility complex expression on human, male germ cells: a review. American Journal of Reproductive Immunology 40. 1998/10/09 ednGoogle Scholar
  11. 11.
    Fiszer D, Kurpisz M (1998) Major histocompatibility complex expression on human, male germ cells: a review. American journal of reproductive immunology, vol 40, 1998/10/09 ednGoogle Scholar
  12. 12.
    PF Robbins, SH Kassim, TL Tran, JS Crystal, RA Morgan, SA Feldman, JC Yang, ME Dudley, JR Wunderlich, RM Sherry, US Kammula, MS Hughes, NP Restifo, MRaffeld, CC Lee, YF Li, M El-Gamil, SA Rosenberg (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21, 2014/12/30 edn.  https://doi.org/10.1158/1078-0432.CCR-14-2708
  13. 13.
    K Odunsi, J Matsuzaki, J Karbach, A Neumann, P Mhawech-Fauceglia, A Miller, A Beck, CD Morrison, G Ritter, H Godoy, S Lele, N Dupont, R Edwards, P Shrikant, LJ Old, S Gnjatic, E Jager (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 109, 2012/03/29 edn.  https://doi.org/10.1073/pnas.1117208109
  14. 14.
    WH Kruit, S Suciu, B Dreno, L Mortier, C Robert, V Chiarion-Sileni, M Maio, A Testori, T Dorval, JJ Grob, JC Becker, A Spatz, AM Eggermont, J Louahed, FF Lehmann, VG Brichard, U Keilholz (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer melanoma Group in Metastatic Melanoma. J Clin Oncol 31. 2013/05/30 edn.  https://doi.org/10.1200/JCO.2012.43.7111
  15. 15.
    J Vansteenkiste, M Zielinski, A Linder, J Dahabreh, EE Gonzalez, W Malinowski, M Lopez-Brea, T Vanakesa, J Jassem, H Kalofonos, J Perdeus, R Bonnet, J Basko, R Janilionis, B Passlick, T Treasure, M Gillet, FF Lehmann, VG Brichard (2013) Adjuvant MAGE-A3 immunotherapy in resected nonsmall-cell Lung Cancer: phase II randomized study results. J Clin Oncol 31. 2013/05/30 edn.  https://doi.org/10.1200/JCO.2012.43.7103
  16. 16.
    DW Cramer, AF Vitonis, SP Pinheiro, JR McKolanis, RN Fichorova, KE Brown, TF Hatchette, OJ Finn (2010) Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control 21. 2010/06/19 edn.  https://doi.org/10.1007/s10552-010-9546-1
  17. 17.
    JD Stone, DT Harris, DM Kranz (2015) TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol 33, 2015/01/27 edn. doi:  https://doi.org/10.1016/j.coi.2015.01.003
  18. 18.
    M Aleksic, N Liddy, PE Molloy, N Pumphrey, A Vuidepot, KM Chang, BK Jakobsen (2012) Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 42, 2012/09/06 edn.  https://doi.org/10.1002/eji.201242606
  19. 19.
    MH Chang, SL You, CJ Chen, CJ Liu, CM Lee, SM Lin, HC Chu, TC Wu, SS Yang, HS Kuo, DS Chen, G Taiwan Hepatoma Study (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101. 2009/09/18 edn.  https://doi.org/10.1093/jnci/djp288
  20. 20.
    CH Wang, KC Wey, LR Mo, KK Chang, RC Lin, JJ Kuo (2015) Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev 16. 2015/05/20 ednGoogle Scholar
  21. 21.
    M Arbyn, L Xu, C Simoens, PP Martin-Hirsch (2018) Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 5, 2018/05/10 edn.  https://doi.org/10.1002/14651858.CD009069.pub3
  22. 22.
    SL Osborne, SN Tabrizi, JM Brotherton, AM Cornall, JD Wark, CD Wrede, Y Jayasinghe, DM Gertig, MK Pitts, SM Garland, VS group (2015) Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 33, 2014/12/03 edn.  https://doi.org/10.1016/j.vaccine.2014.10.045
  23. 23.
    R Govindan, L Ding, M Griffith, J Subramanian, ND Dees, KL Kanchi, CA Maher, R Fulton, L Fulton, J Wallis, K Chen, J Walker, S McDonald, R Bose, D Ornitz, D Xiong, M You, DJ Dooling, M Watson, ER Mardis, RK Wilson (2012) Genomic landscape of non-small cell lung cancer in smokers and neversmokers. Cell 150. 2012/09/18 edn.  https://doi.org/10.1016/j.cell.2012.08.024
  24. 24.
    DE Brash (2015) UV signature mutations. Photochem Photobiol 91. 2014/10/30 edn.  https://doi.org/10.1111/php.12377
  25. 25.
    Le DT, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, H Kemberling, C Wilt, BS Luber, F Wong, NS Azad, AA Rucki, D Laheru, R Donehower, A Zaheer, GA Fisher, TS Crocenzi, JJ Lee, TF Greten, AG Duffy, KK Ciombor, AD Eyring, BH Lam, A Joe, SP Kang, M Holdhoff, L Danilova, L Cope, C Meyer, S Zhou, RM Goldberg, DK Armstrong, KM Bever, AN Fader, J Taube, F Housseau, D Spetzler, N Xiao, DM Pardoll, N Papadopoulos, KW Kinzler, JR Eshleman, B Vogelstein, RA Anders, LA Diaz, Jr (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357. 2017/06/10 edn.  https://doi.org/10.1126/science.aan6733
  26. 26.
    B Vogelstein, N Papadopoulos, VE Velculescu, S Zhou, LA Diaz, Jr., KW Kinzler (2013) Cancer genome landscapes. Science 339. 2013/03/30 edn doi:  https://doi.org/10.1126/science.1235122
  27. 27.
    CJ Cohen, JJ Gartner, M Horovitz-Fried, K Shamalov, K Trebska-McGowan, VV Bliskovsky, MR Parkhurst, C Ankri, TD Prickett, JS Crystal, YF Li, M El-Gamil, SA Rosenberg, PF Robbins (2015) Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. The J Clin Investig 125. 2015/09/22 edn.  https://doi.org/10.1172/JCI82416
  28. 28.
    V Lennerz, M Fatho, C Gentilini, RA Frye, A Lifke, D Ferel, C Wolfel, C Huber, T Wolfel (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 102. 2005/10/26 edn.  https://doi.org/10.1073/pnas.0500090102
  29. 29.
    E Tran, PF Robbins, YC Lu, TD Prickett, JJ Gartner, L Jia, A Pasetto, Z Zheng, S Ray, EM Groh, IR Kriley, SA Rosenberg (2016) T-cell transfer therapy targeting mutant KRAS in Cancer. N Engl J Med 375. 2016/12/14 edn. doi:  https://doi.org/10.1056/NEJMoa1609279
  30. 30.
    E Stronen, M Toebes, S Kelderman, MM van Buuren, W Yang, N van Rooij, M Donia, ML Boschen, F Lund-Johansen, J Olweus, TN Schumacher (2016) Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352. 2016/05/21 edn.  https://doi.org/10.1126/science.aaf2288
  31. 31.
    M Yarchoan, BA Johnson, 3rd, ER Lutz, DA Laheru, EM Jaffee (2017) Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17. 2017/08/25 edn.  https://doi.org/10.1038/nrc.2017.74
  32. 32.
    PF Robbins, YC Lu, M El-Gamil, YF Li, C Gross, J Gartner, JC Lin, JK Teer, P Cliften, E Tycksen, Y Samuels, SA Rosenberg (2013) mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumorreactive T cells. Nat Med 19. 2013/05/07 edn.  https://doi.org/10.1038/nm.3161
  33. 33.
    O Tureci, M Vormehr, M Diken, S Kreiter, C Huber, U Sahin (2016) Targeting the heterogeneity of Cancer with individualized Neoepitope vaccines. Clin Cancer Res 22.  https://doi.org/10.1158/1078-0432.CCR-15-1509
  34. 34.
    PA Ott, Z Hu, DB Keskin, SA Shukla, J Sun, DJ Bozym, W Zhang, A Luoma, A Giobbie-Hurder, L Peter, C Chen, O Olive, TA Carter, S Li, DJ Lieb, T Eisenhaure, E Gjini, J Stevens, WJ Lane, I Javeri, K Nellaiappan, AM Salazar, H Daley, M Seaman, EI Buchbinder, CH Yoon, M Harden, N Lennon, S Gabriel, SJ Rodig, DH Barouch, JC Aster, G Getz, K Wucherpfennig, D Neuberg, J Ritz, ES Lander, EF Fritsch, N Hacohen, CJ Wu (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 2017/07/06 edn.  https://doi.org/10.1038/nature22991
  35. 35.
    U Sahin, E Derhovanessian, M Miller, BP Kloke, P Simon, M Lower, V Bukur, AD Tadmor, U Luxemburger, B Schrors, T Omokoko, M Vormehr, C Albrecht, A Paruzynski, AN Kuhn, J Buck, S Heesch, KH Schreeb, F Muller, I Ortseifer, I Vogler, E Godehardt, S Attig, R Rae, A Breitkreuz, C Tolliver, M Suchan, G Martic, A Hohberger, P Sorn, J Diekmann, J Ciesla, O Waksmann, AK Bruck, M Witt, M Zillgen, A Rothermel, B Kasemann, D Langer, S Bolte, M Diken, S Kreiter, R Nemecek, C Gebhardt, S Grabbe, C Holler, J Utikal, C Huber, C Loquai, O Tureci (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547. 2017/07/06 edn.  https://doi.org/10.1038/nature23003
  36. 36.
    BM Carreno, V Magrini, M Becker-Hapak, S Kaabinejadian, J Hundal, AA Petti, A Ly, WR Lie, WH Hildebrand, ER Mardis, GP Linette (2015) Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigenspecific T cells. Science 348.  https://doi.org/10.1126/science.aaa3828
  37. 37.
    P Busek, R Mateu, M Zubal, L Kotackova, A Sedo (2018) Targeting fibroblast activation protein in cancer—prospects andcaveats. Front Biosci (landmark Ed) 23. 2018/05/18 ednGoogle Scholar
  38. 38.
    MH Andersen (2018) The balance players of the adaptive immune system. Cancer Res 78, 2018/02/15 edn.  https://doi.org/10.1158/0008-5472.CAN-17-3607
  39. 39.
    SC Wagner, NH Riordan, TE Ichim, J Szymanski, H Ma, JA Perez, J Lopez, JJ Plata-Munoz, F Silva, AN Patel, S Kesari (2016) Safety of targeting tumor endothelial cell antigens. J Transl Med 14. 2016/04/14 edn. doi:  https://doi.org/10.1186/s12967-016-0842-8
  40. 40.
    FH Schmitz-Winnenthal, N Hohmann, T Schmidt, L Podola, T Friedrich, H Lubenau, M Springer, S Wieckowski, KM Breiner, G Mikus, MW Buchler, AV Keller, R Koc, C Springfeld, P Knebel, M Bucur, L Grenacher, WE Haefeli, P Beckhove (2018) A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology 7. 2018/04/11 edn.  https://doi.org/10.1080/2162402X.2017.1303584
  41. 41.
    CA Klebanoff, JD Wolchok (2018) Shared cancer neoantigens: making private matters public. J Exp Med 215, 2017/12/23 edn.  https://doi.org/10.1084/jem.20172188
  42. 42.
    F Benchetrit, A Gazagne, O Adotevi, N Haicheur, B Godard, C Badoual, WH Fridman, E Tartour (2003) Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy. Bull Cancer 90Google Scholar
  43. 43.
    T Tran, MO Diniz, E Dransart, A Gey, N Merillon, YC Lone, S Godefroy, C Sibley, LC Ferreira, J Medioni, S Oudard, L Johannes, E Tartour (2016) A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu-expressing tumor in HLA-A2 transgenic mice. Clin Cancer Res 22  https://doi.org/10.1158/1078-0432.CCR-16-0044
  44. 44.
    AF Carpentier, F Geinguenaud, T Tran, F Sejalon, A Martin, L Motte, E Tartour, C Banissi (2017) Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. PLoS One 12. 2017/07/18 edn.  https://doi.org/10.1371/journal.pone.0181403
  45. 45.
    C Lonchay, P van der Bruggen, T Connerotte, T Hanagiri, P Coulie, D Colau, S Lucas, A Van Pel, K Thielemans, N van Baren, T Boon (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 101 Suppl 2Google Scholar
  46. 46.
    JC Becker, MH Andersen, V Hofmeister-Muller, M Wobser, L Frey, C Sandig, S Walter, H Singh-Jasuja, E Kampgen, A Opitz, M Zapatka, EB Brocker, P Thor Straten, D Schrama, S Ugurel (2012) Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 61. 2012/05/09 edn.  https://doi.org/10.1007/s00262-012-1266-9
  47. 47.
    DP Carbone, IF Ciernik, MJ Kelley, MC Smith, S Nadaf, D Kavanaugh, VE Maher, M Stipanov, D Contois, BE Johnson, CD Pendleton, B Seifert, C Carter, EJ Read, J Greenblatt, LE Top, MI Kelsey, JD Minna, JA Berzofsky (2005) Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23. 2005/06/29 edn. doi: 10.1200/JCO.2005.03.158Google Scholar
  48. 48.
    C Granier, C Blanc, S Karaki, T Tran, H Roussel, E Tartour (2017) Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines. Oncoimmunology 6. 2017/11/18 edn. doi:  https://doi.org/10.1080/2162402X.2017.1358841
  49. 49.
    M Nizard, H Roussel, MO Diniz, S Karaki, T Tran, T Voron, E Dransart, F Sandoval, M Riquet, B Rance, E Marcheteau, E Fabre, M Mandavit, M Terme, C Blanc, JB Escudie, L Gibault, FLP Barthes, C Granier, LCS Ferreira, C Badoual, L Johannes, E Tartour (2017) Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun 8.  https://doi.org/10.1038/ncomms15221
  50. 50.
    T Murray, SA Fuertes Marraco, P Baumgaertner, N Bordry, L Cagnon, A Donda, P Romero, G Verdeil, DE Speiser (2016) Very late Antigen-1 marks functional tumor-resident CD8 T cells and correlates with survival of melanoma patients. Front Immunol 7.  https://doi.org/10.3389/fimmu.2016.00573
  51. 51.
    S Iborra, M Martinez-Lopez, SC Khouili, M Enamorado, FJ Cueto, R Conde-Garrosa, C Del Fresno, D Sancho (2016) Optimal generation of tissue-resident but not circulating memory Tcells during viral infection requires Crosspriming by DNGR-1(+) dendritic cells. Immunity 45. 2016/10/21 edn.  https://doi.org/10.1016/j.immuni.2016.08.019
  52. 52.
    L Fong, P Carroll, V Weinberg, S Chan, J Lewis, J Corman, CL Amling, RA Stephenson, J Simko, NA Sheikh, RB Sims, MW Frohlich, EJ Small (2014) Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 106. 2014/09/27 edn.  https://doi.org/10.1093/jnci/dju268
  53. 53.
    JB Haanen, A Baars, R Gomez, P Weder, M Smits, TD de Gruijl, BM von Blomberg, E Bloemena, RJ Scheper, SM van Ham, HM Pinedo, AJ van den Eertwegh (2006) Melanoma-specific tumorinfiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55. 2005/07/22 edn.  https://doi.org/10.1007/s00262-005-0018-5
  54. 54.
    BI Rini, A Stenzl, R Zdrojowy, M Kogan, M Shkolnik, S Oudard, S Weikert, S Bracarda, SJ Crabb, J Bedke, J Ludwig, D Maurer, R Mendrzyk, C Wagner, A Mahr, J Fritsche, T Weinschenk, S Walter, A Kirner, H Singh-Jasuja, C Reinhardt, T Eisen (2016) IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17. 2016/10/11 edn.  https://doi.org/10.1016/S1470-2045(16)30408-9
  55. 55.
    KH Lee, E Wang, MB Nielsen, J Wunderlich, S Migueles, M Connors, SM Steinberg, SA Rosenberg, FM Marincola (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163Google Scholar
  56. 56.
    V Corbiere, J Chapiro, V Stroobant, W Ma, C Lurquin, B Lethe, N van Baren, BJ Van den Eynde, T Boon, PG Coulie (2011) Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 71. 2011/01/11 EDN  https://doi.org/10.1158/0008-5472.CAN-10-2693
  57. 57.
    JL Gulley, RA Madan, R Pachynski, P Mulders, NA Sheikh, J Trager, CG Drake (2017) Role of antigen spread and distinctive characteristics of immunotherapy in Cancer treatment. J Natl Cancer Inst 109. 2017/04/05 edn.  https://doi.org/10.1093/jnci/djw261
  58. 58.
    LH Butterfield, A Ribas, VB Dissette, SN Amarnani, HT Vu, D Oseguera, HJ Wang, RM Elashoff, WH McBride, B Mukherji, AJ Cochran, JA Glaspy, JS Economou (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9Google Scholar
  59. 59.
    GQ Phan, CE Touloukian, JC Yang, NP Restifo, RM Sherry, P Hwu, SL Topalian, DJ Schwartzentruber, CA Seipp, LJ Freezer, KE Morton, SA Mavroukakis, DE White, SA Rosenberg (2003) Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanomaassociated antigens. J Immunother 26, 2003/07/05 ednGoogle Scholar
  60. 60.
    V Lennerz, S Gross, E Gallerani, C Sessa, N Mach, S Boehm, D Hess, L von Boehmer, A Knuth, AF Ochsenbein, U Gnad-Vogt, J Zieschang, U Forssmann, T Woelfel, E Kaempgen (2014) Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 63. 2014/02/04 edn. doi:  https://doi.org/10.1007/s00262-013-1516-5
  61. 61.
    E Mizukoshi, H Nakagawa, M Kitahara, T Yamashita, K Arai, H Sunagozaka, K Fushimi, E Kobayashi, H Kishi, A Muraguchi, S Kaneko (2015) Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. Cancer Lett 364. 2015/05/20 edn.  https://doi.org/10.1016/j.canlet.2015.04.031
  62. 62.
    R Patil, GT Clifton, JP Holmes, A Amin, MG Carmichael, JD Gates, LH Benavides, MT Hueman, S Ponniah, GE Peoples (2010) Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg 210.  https://doi.org/10.1016/j.jamcollsurg.2009.10.022
  63. 63.
    PJ Schuler, M Harasymczuk, C Visus, A Deleo, S Trivedi, Y Lei, A Argiris, W Gooding, LH Butterfield, TL Whiteside, RL Ferris (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20. 2014/03/04 edn.  https://doi.org/10.1158/1078-0432.CCR-13-2617
  64. 64.
    LV Wood, A Fojo, BD Roberson, MS Hughes, W Dahut, JL Gulley, RA Madan, PM Arlen, M Sabatino, DF Stroncek, L Castiello, JB Trepel, MJ Lee, HL Parnes, SM Steinberg, M Terabe, J Wilkerson, I Pastan, JA Berzofsky (2016) TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with stage D0 prostate cancer. Oncoimmunology 5. 2016/09/14 edn.  https://doi.org/10.1080/2162402X.2016.1197459
  65. 65.
    P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, AA Jungbluth, G Ritter, C Aghajanian, K Bell-McGuinn, ML Hensley, J Konner, W Tew, DR Spriggs, EW Hoffman, R Venhaus, L Pan, AM Salazar, CM Diefenbach, LJ Old, S Gnjatic (2012) Phase I trial of overlapping long peptides from a Semin Immunopathol tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 18. 2012/10/04 edn  https://doi.org/10.1158/1078-0432.CCR-12-2189
  66. 66.
    N Suzuki, S Hazama, T Ueno, H Matsui, Y Shindo, M Iida, K Yoshimura, S Yoshino, K Takeda, M Oka (2014) A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37. 2013/12/10 edn.  https://doi.org/10.1097/CJI.0000000000000012
  67. 67.
    K Kakimi, M Isobe, A Uenaka, H Wada, E Sato, Y Doki, J Nakajima, Y Seto, T Yamatsuji, Y Naomoto, K Shiraishi, N Takigawa, K Kiura, K Tsuji, K Iwatsuki, M Oka, L Pan, EW Hoffman, LJ Old, E Nakayama (2011) A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NYESO- 1 antigen. Int J Cancer 129. 2011/03/31 edn.  https://doi.org/10.1002/ijc.25955
  68. 68.
    U Sahin, O Tureci (2018) Personalized vaccines for cancer immunotherapy. Science 359. 2018/03/24 edn.  https://doi.org/10.1126/science.aar7112
  69. 69.
    Z Hu, PA Ott, CJ Wu (2018) Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol 18. 2017/12/12 edn.  https://doi.org/10.1038/nri.2017.131
  70. 70.
    AH Banday, S Jeelani, VJ Hruby (2015) Cancer vaccine adjuvants–recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 37. 2014/10/17 edn.  https://doi.org/10.3109/08923973.2014.971963
  71. 71.
    S van Duikeren, MF Fransen, A Redeker, B Wieles, G Platenburg, WJ Krebber, F Ossendorp, CJ Melief, R Arens (2012) vaccineinduced effector-memory CD8+ Tcell responses predict therapeutic efficacy against tumors. J Immunol 189. 2012/08/24 edn.  https://doi.org/10.4049/jimmunol.1201540
  72. 72.
    DE Speiser, D Lienard, N Rufer, V Rubio-Godoy, D Rimoldi, F Lejeune, AM Krieg, JC Cerottini, P Romero (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115Google Scholar
  73. 73.
    R Perret, SR Sierro, NK Botelho, S Corgnac, A Donda, P Romero (2013) Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 73. 2013/09/21 edn.  https://doi.org/10.1158/0008-5472.CAN-13-0875
  74. 74.
    RD Junkins, MD Gallovic, BM Johnson, MA Collier, R Watkins-Schulz, N Cheng, CN David, CE McGee, GD Sempowski, I Shterev, K McKinnon, EM Bachelder, KM Ainslie, JP Ting (2018) A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release : official journal of the Controlled Release Society 270. 2017/11/25 edn.  https://doi.org/10.1016/j.jconrel.2017.11.030
  75. 75.
    C Larocca, J Schlom (2011) Viral vector-based therapeutic cancer vaccines. Cancer J 17. 2011/09/29 edn.  https://doi.org/10.1097/PPO.0b013e3182325e63
  76. 76.
    R Cawood, T Hills, SL Wong, AA Alamoudi, S Beadle, KD Fisher, LW Seymour (2012) Recombinant viral vaccines for cancer. Trends Mol Med 18. 2012/08/25 edn.  https://doi.org/10.1016/j.molmed.2012.07.007
  77. 77.
    S Yang, JW Hodge, DW Grosenbach, J Schlom (2005) Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol 175. 2005/09/09 ednGoogle Scholar
  78. 78.
    JL Gulley, PM Arlen, KY Tsang, J Yokokawa, C Palena, DJ Poole, C Remondo, V Cereda, JL Jones, MP Pazdur, JP Higgins, JW Hodge, SM Steinberg, H Kotz, WL Dahut, J Schlom (2008) Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14. 2008/05/17 edn.  https://doi.org/10.1158/1078-0432.CCR-08-0126
  79. 79.
    PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, M Wyand, K Manson, DL Panicali, R Laus, J Schlom, WL Dahut, PM Arlen, JL Gulley, WR Godfrey (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate Cancer J Clin Oncol 28. 2010/01/27 EDN  https://doi.org/10.1200/JCO.2009.25.0597
  80. 80.
    S Sau, HO Alsaab, K Bhise, R Alzhrani, G Nabil, AK Iyer (2018) Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment. J Control 274. 2018/02/03 edn.  https://doi.org/10.1016/j.jconrel.2018.01.028
  81. 81.
    CR Alving, Z Beck, GR Matyas, M Rao (2016) Liposomal adjuvants for human vaccines. Expert Opin Drug Deliv 13. 2016/02/13 edn.  https://doi.org/10.1517/17425247.2016.1151871
  82. 82.
    EM Varypataki, AL Silva, C Barnier-Quer, N Collin, F Ossendorp, W Jiskoot (2016) Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: a comparative study of cationic liposomes and PLGA nanoparticles. J Control Release 226. 2016/02/16 edn.  https://doi.org/10.1016/j.jconrel.2016.02.018
  83. 83.
    Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351–360CrossRefPubMedGoogle Scholar
  84. 84.
    van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Lowik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH (2016) Vaccination against Oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response. Clin Cancer Res 22.  https://doi.org/10.1158/1078-0432.CCR-15-2594
  85. 85.
    E Segura, S Amigorena (2015) Cross-presentation in mouse and human dendritic cells. Adv Immunol 127. 2015/06/16 edn.  https://doi.org/10.1016/bs.ai.2015.03.002
  86. 86.
    Macri C, Dumont C, Johnston AP, Mintern JD (2016) Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Clin Transl Immunol 5.  https://doi.org/10.1038/cti.2016.6
  87. 87.
    Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, Goud B, Fridman WH, Johannes L, Tartour E (2000) The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol 165Google Scholar
  88. 88.
    O Adotevi, B Vingert, L Freyburger, P Shrikant, YC Lone, F Quintin-Colonna, N Haicheur, M Amessou, A Herbelin, P Langlade-Demoyen, WH Fridman, F Lemonnier, L Johannes, E Tartour (2007) B subunit of Shiga toxin-based vaccines synergize with {alpha}-Galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 179Google Scholar
  89. 89.
    H Pere, Y Montier, J Bayry, F Quintin-Colonna, N Merillon, E Dransart, C Badoual, A Gey, P Ravel, E Marcheteau, F Batteux, F Sandoval, O Adotevi, C Chiu, S Garcia, C Tanchot, YC Lone, LC Ferreira, BH Nelson, D Hanahan, WH Fridman, L Johannes, E Tartour (2011) A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 118. 2011/09/13 EDN  https://doi.org/10.1182/blood-2011-01-329656
  90. 90.
    N Chaoul, A Tang, B Desrues, M Oberkampf, C Fayolle, D Ladant, A Sainz-Perez, C Leclerc (2018) Lack of MHC class II molecules favors CD8(+) T-cell infiltration into tumors associated with an increased control of tumor growth. Oncoimmunology 7. 2018/02/06 edn.  https://doi.org/10.1080/2162402X.2017.1404213
  91. 91.
    D Terhorst, E Fossum, A Baranska, S Tamoutounour, C Malosse, M Garbani, R Braun, E Lechat, R Crameri, B Bogen, S Henri, B Malissen (2015) Laser-assisted intradermal delivery of adjuvantfree vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses. J Immunol 194, 2015/05/06 edn. doi:  https://doi.org/10.4049/jimmunol.1500564
  92. 92.
    G Picco, R Beatson, J Taylor-Papadimitriou, JM Burchell (2014) Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas. Eur J Immunol 44. 2014/03/22 edn.  https://doi.org/10.1002/eji.201344076
  93. 93.
    T Tsuji, J Matsuzaki, MP Kelly, V Ramakrishna, LVitale, LZ He, T Keler, K Odunsi, LJ Old, G Ritter, S Gnjatic (2011) Antibodytargeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol 186. 2010/12/15 edn.  https://doi.org/10.4049/jimmunol.1000808
  94. 94.
    KM Tullett, IM Leal Rojas, Y Minoda, PS Tan, JG Zhang, C Smith, R Khanna, K Shortman, I Caminschi, MH Lahoud, KJ Radford (2016) Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition. JCI Insight 1. 2016/10/05 edn.  https://doi.org/10.1172/jci.insight.87102
  95. 95.
    JL Tanyi, S Bobisse, E Ophir, S Tuyaerts, A Roberti, R Genolet, P Baumgartner, BJ Stevenson, C Iseli, D Dangaj, B Czerniecki, A Semilietof, J Racle, A Michel, I Xenarios, C Chiang, DS Monos, DA Torigian, HL Nisenbaum, O Michielin, CH June, BL Levine, DJ Powell, Jr., D Gfeller, R Mick, U Dafni, V Zoete, A Harari, G Coukos, LE Kandalaft (2018) Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med 10. 2018/04/13 edn.  https://doi.org/10.1126/scitranslmed.aao5931
  96. 96.
    MNizard, MO Diniz, H Roussel, T Tran, LC Ferreira, C Badoual, E Tartour (2014) Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. Hum Vaccin Immunother 10.  https://doi.org/10.4161/hv.29269
  97. 97.
    F Sandoval, M Terme, M Nizard, C Badoual, MF Bureau, L Freyburger, O Clement, E Marcheteau, A Gey, G Fraisse, C Bouguin, N Merillon, E Dransart, T Tran, F Quintin-Colonna, G Autret, M Thiebaud, M Suleman, S Riffault, TC Wu, O Launay, C Danel, J Taieb, J Richardson, L Zitvogel, WH Fridman, L Johannes, E Tartour (2013) mucosal imprinting of vaccineinduced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 5. 2013/02/15 edn.  https://doi.org/10.1126/scitranslmed.3004888
  98. 98.
    YY Sun, S Peng, L Han, J Qiu, L Song, Y Tsai, B Yang, RB Roden, CL Trimble, CF Hung, TC Wu (2016) Local HPV recombinant vaccinia boost following priming with an HPV DNA vaccine enhances local HPV-specific CD8+ T-cell-mediated tumor control in the genital tract. Clin Cancer Res 22.  https://doi.org/10.1158/1078-0432.CCR-15-0234
  99. 99.
    M Nizard, H Roussel, E Tartour (2016) Resident memory T cells as surrogate markers of the efficacy of Cancer vaccines. Clin Cancer Res 22.  https://doi.org/10.1158/1078-0432.CCR-15-2364
  100. 100.
    SR Bennett, FR Carbone, F Karamalis, RA Flavell, JF Miller, WR Heath (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling [see comments]. Nature 393Google Scholar
  101. 101.
    CM Smith, NS Wilson, J Waithman, JA Villadangos, FR Carbone, WR Heath, GT Belz (2004) Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5. 2004/10/12 edn.  https://doi.org/10.1038/ni1129
  102. 102.
    R Bos, LA Sherman (2010) CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70. 2010/10/14 edn.  https://doi.org/10.1158/0008-5472.CAN-10-1322
  103. 103.
    Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421Google Scholar
  104. 104.
    Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, Griffith TS, Green DR, Schoenberger SP (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434Google Scholar
  105. 105.
    BJ Laidlaw, JE Craft, SM Kaech (2016) The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat Rev Immunol 16. 2016/01/20 edn.  https://doi.org/10.1038/nri.2015.10
  106. 106.
    B Rocha, C Tanchot (2004) Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol 16. 2004/05/12 edn.  https://doi.org/10.1016/j.coi.2004.03.004
  107. 107.
    SA Quezada, TR Simpson, KS Peggs, T Merghoub, J Vider, X Fan, R Blasberg, H Yagita, P Muranski, PA Antony, NP Restifo, JP Allison (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207. 2010/02/17 edn.  https://doi.org/10.1084/jem.20091918
  108. 108.
    J Galaine, C Borg, Y Godet, O Adotevi (2015) Interest of tumorspecific CD4 T helper 1 cells for therapeutic anticancer vaccine. Vaccines 3. 2015/09/10 edn.  https://doi.org/10.3390/vaccines3030490
  109. 109.
    Qin Z, Blankenstein T (2000) CD4+ T cell–mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12Google Scholar
  110. 110.
    L Tian, A Goldstein, H Wang, H Ching Lo, I Sun Kim, T Welte, K Sheng, LE Dobrolecki, X Zhang, N Putluri, TL Phung, SA Mani, F Stossi, A Sreekumar, MA Mancini, WK Decker, C Zong, MT Lewis, XH Zhang (2017) Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544. 2017/04/04 edn.  https://doi.org/10.1038/nature21724
  111. 111.
    NN Hunder, H Wallen, J Cao, DW Hendricks, JZ Reilly, R Rodmyre, A Jungbluth, S Gnjatic, JA Thompson, C Yee (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358. 2008/06/21 EDN  https://doi.org/10.1056/NEJMoa0800251
  112. 112.
    E Tran, S Turcotte, A Gros, PF Robbins, YC Lu, ME Dudley, JR Wunderlich, RP Somerville, K Hogan, CS Hinrichs, MR Parkhurst, JC Yang, SA Rosenberg (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344. 2014/05/09 edn.  https://doi.org/10.1126/science.1251102
  113. 113.
    J Matsuzaki, T Tsuji, IF Luescher, H Shiku, J Mineno, S Okamoto, LJ Old, P Shrikant, S Gnjatic, K Odunsi (2015) Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep 5. 2015/10/09 edn.  https://doi.org/10.1038/srep14896
  114. 114.
    Y Godet, E Fabre, M Dosset, M Lamuraglia, E Levionnois, P Ravel, N Benhamouda, A Cazes, F Le Pimpec-Barthes, B Gaugler, P Langlade-Demoyen, X Pivot, P Saas, B Maillere, E Tartour, C Borg, O Adotevi (2012) Analysis of spontaneous tumor-specific CD4 T-cell immunity in Lung Cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Semin Immunopathol Res 18. 2012/03/13 EDN  https://doi.org/10.1158/1078-0432.CCR-11-3185
  115. 115.
    Y Hu, H Kim, CM Blackwell, CL Slingluff, Jr (2015) Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg 262. 2015/08/11 edn.  https://doi.org/10.1097/SLA.0000000000001419
  116. 116.
    J Datta, M Fracol, MT McMillan, E Berk, S Xu, N Goodman, DA Lewis, A DeMichele, BJ Czerniecki (2016) Association of Depressed Anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast Cancer: role for immune monitoring. JAMA Oncol 2. 2016/01/01 edn.  https://doi.org/10.1001/jamaoncol.2015.5482
  117. 117.
    S Kreiter, M Vormehr, N van de Roemer, M Diken, M Lower, J Diekmann, S Boegel, B Schrors, F Vascotto, JC Castle, AD Tadmor, SP Schoenberger, C Huber, O Tureci, U Sahin (2015) Mutant MHCclass II epitopes drive therapeutic immune responses to cancer. Nature 520. 2015/04/23 edn.  https://doi.org/10.1038/nature14426
  118. 118.
    T Schumacher, L Bunse, S Pusch, F Sahm, B Wiestler, J Quandt, O Menn, M Osswald, I Oezen, M Ott, M Keil, J Balss, K Rauschenbach, AK Grabowska, I Vogler, J Diekmann, N Trautwein, SB Eichmuller, J Okun, S Stevanovic, AB Riemer, U Sahin, MA Friese, P Beckhove, A von Deimling, W Wick, M Platten (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512. 2014/07/22 edn.  https://doi.org/10.1038/nature13387
  119. 119.
    RC Kennedy, MH Shearer, AM Watts, Bright RK (2003) CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res 63. 2003/03/05 ednGoogle Scholar
  120. 120.
    Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90Google Scholar
  121. 121.
    CL Slingluff Jr, GR Petroni, KA Chianese-Bullock, ME Smolkin, MI Ross, NB Haas, M von Mehren, WW Grosh (2011) Randomized multicenter trial of the effects of melanomaassociated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma Vaccine J Clin Oncol 29. 2011/06/22 EDN  https://doi.org/10.1200/JCO.2010.33.8053
  122. 122.
    EH Aarntzen, IJ De Vries, WJ Lesterhuis, D Schuurhuis, JF Jacobs, K Bol, G Schreibelt, R Mus, JH De Wilt, JB Haanen, D Schadendorf, A Croockewit, WA Blokx, MM Van Rossum, WW Kwok, GJ Adema, CJ Punt, CG Figdor (2013) Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 73. 2012/10/23 edn.  https://doi.org/10.1158/0008-5472.CAN-12-1127
  123. 123.
    SH van der Burg (2018) Correlates of immune and clinical activity of novel cancer vaccines. Semin Immunol. 2018/05/02 edn.  https://doi.org/10.1016/j.smim.2018.04.001
  124. 124.
    S Gnjatic, NK Altorki, DN Tang, SM Tu, V Kundra, G Ritter, LJ Old, CJ Logothetis, P Sharma (2009) NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 15. 2009/03/12 edn.  https://doi.org/10.1158/1078-0432.CCR-08-2632
  125. 125.
    G Zhou, CG Drake, HI Levitsky (2006) Amplification of tumorspecific regulatory T cells following therapeutic cancer vaccines. Blood 107. 2005/09/24 edn.  https://doi.org/10.1182/blood-2005-07-2737
  126. 126.
    C Butts, MA Socinski, PL Mitchell, N Thatcher, L Havel, M Krzakowski, S Nawrocki, TE Ciuleanu, L Bosquee, JM Trigo, A Spira, L Tremblay, J Nyman, R Ramlau, G Wickart-Johansson, P Ellis, O Gladkov, JR Pereira, WE Eberhardt, C Helwig, A Schroder, FA Shepherd (2014) Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage III non-small-cell Lung Cancer (START): a randomised, doubleblind, phase 3 Trials Lancet Oncol 15. 2013/12/18 EDN ,  https://doi.org/10.1016/S1470-2045(13)70510-2
  127. 127.
    JF Vansteenkiste, BC Cho, T Vanakesa, T De Pas, M Zielinski, MS Kim, J Jassem, M Yoshimura, J Dahabreh, H Nakayama, L Havel, H Kondo, T Mitsudomi, K Zarogoulidis, OA Gladkov, K Udud, H Tada, H Hoffman, A Bugge, P Taylor, EE Gonzalez, ML Liao, J He, JL Pujol, J Louahed, M Debois, V Brichard, C Debruyne, P Therasse, N Altorki (2016) Efficacy of the MAGEA3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17. 2016/05/02 edn.  https://doi.org/10.1016/S1470-2045(16)00099-1
  128. 128.
    R Levy, KN Ganjoo, JP Leonard, JM Vose, IW Flinn, RF Ambinder, JM Connors, NL Berinstein, AR Belch, NL Bartlett, C Nichols, CE Emmanouilides, JM Timmerman, SA Gregory, BK Link, DJ Inwards, AS Freedman, JV Matous, MJ Robertson, LA Kunkel, DE Ingolia, AJ Gentles, CL Liu, R Tibshirani, AA Alizadeh, DW Denney, Jr (2014) Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol 32. 2014/05/07 edn.  https://doi.org/10.1200/JCO.2012.43.9273
  129. 129.
    D Schadendorf, S Ugurel, B Schuler-Thurner, FO Nestle, A Enk, EB Brocker, S Grabbe, W Rittgen, L Edler, A Sucker, C Zimpfer-Rechner, T Berger, J Kamarashev, G Burg, H Jonuleit, A Tuttenberg, JC Becker, P Keikavoussi, E Kampgen, G Schuler, DC study group of the DeCOG (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17. 2006/01/19 edn.  https://doi.org/10.1093/annonc/mdj138
  130. 130.
    D GuhaThakurta, NA Sheikh, LQ Fan, H Kandadi, TC Meagher, SJ Hall, PW Kantoff, CS Higano, EJ Small, TA Gardner, K Bailey, T Vu, T DeVries, JB Whitmore, MW Frohlich, JB Trager, CG Drake (2015) Humoral immune response against nontargeted tumor antigens after treatment with Sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res 21. 2015/02/05 edn.  https://doi.org/10.1158/1078-0432.CCR-14-2334
  131. 131.
    Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebocontrolled phase 2b trial. Lancet 386.  https://doi.org/10.1016/S0140-6736(15)00239-1
  132. 132.
    GG Kenter, MJ Welters, AR Valentijn, MJ Lowik, DM Berendsvan der Meer, AP Vloon, F Essahsah, LM Fathers, R Offringa, JW Drijfhout, AR Wafelman, J Oostendorp, GJ Fleuren, SH van der Burg, CJ Melief (2009) vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361. 2009/11/06 edn.  https://doi.org/10.1056/NEJMoa0810097
  133. 133.
    MI van Poelgeest, MJ Welters, EM van Esch, LF Stynenbosch, G Kerpershoek, EL van Persijn van Meerten, M van den Hende, MJ Lowik, DM Berends-van der Meer, LM Fathers, AR Valentijn, J Oostendorp, GJ Fleuren, CJ Melief, GG Kenter, SH van der Burg (2013) HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 11. 2013/04/06 edn.  https://doi.org/10.1186/1479-5876-11-88
  134. 134.
    L Lowenfeld, R Mick, J Datta, S Xu, E Fitzpatrick, CS Fisher, KR Fox, A DeMichele, PJ Zhang, SP Weinstein, RE Roses, BJ Czerniecki (2017) Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial. Clin Cancer Res 23. 2016/12/15 edn.  https://doi.org/10.1158/1078-0432.CCR-16-1924
  135. 135.
    MJ Welters, TC van der Sluis, H van Meir, NM Loof, VJ van Ham, S van Duikeren, SJ Santegoets, R Arens, ML de Kam, AF Cohen, MI van Poelgeest, GG Kenter, JR Kroep, J Burggraaf, CJ Melief, SH van der Burg (2016) Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med 8. 2016/04/15 edn. doi:  https://doi.org/10.1126/scitranslmed.aad8307
  136. 136.
    CJ Melief, ME Gerritsen, MJ Welters, I Vergote, JR Kroep, GG Kenter, PB Ottevanger, TA Tjalma, H Denys, H Nijman, van Poelgeest MIE, AKL Reyners, TJ Velu, BA Blumenstein, F Goffin, RI Lalisang, RB Stead, SH Van der Burg (2017) Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical Cancer In: ASCO SITC Clinical immuno-oncology symposium, Oralando (FL), 2017. J Clin OncolGoogle Scholar
  137. 137.
    A Cadena, TR Cushman, C Anderson, HB Barsoumian, JW Welsh, MA Cortez (2018) Radiation and anti-Cancer vaccines: a winning combination. Vaccines 6. 2018/02/02 edn.  https://doi.org/10.3390/vaccines6010009
  138. 138.
    M Mondini, M Nizard, T Tran, L Mauge, M Loi, C Clemenson, D Dugue, P Maroun, E Louvet, J Adam, C Badoual, D Helley, E Dransart, L Johannes, MC Vozenin, JL Perfettini, E Tartour, E Deutsch (2015) Synergy of radiotherapy and a Cancer vaccine for the treatment of HPV-associated head and neck Cancer. Mol Cancer Ther 14.  https://doi.org/10.1158/1535-7163.MCT-14-1015
  139. 139.
    M Huo, Y Zhao, AB Satterlee, Y Wang, Y Xu, L Huang (2017) Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release 245. 2016/11/20 edn.  https://doi.org/10.1016/j.jconrel.2016.11.013
  140. 140.
    H Pere, C Tanchot, J Bayry, M Terme, J Taieb, C Badoual, O Adotevi, N Merillon, E Marcheteau, VR Quillien, C Banissi, A Carpentier, F Sandoval, M Nizard, F Quintin-Colonna, G Kroemer, WH Fridman, L Zitvogel, SP Oudard, E Tartour (2012) comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 1. 2012/06/ 28 edn.  https://doi.org/10.4161/onci.18852
  141. 141.
    TR Simpson, F Li, W Montalvo-Ortiz, MA Sepulveda, K Bergerhoff, F Arce, C Roddie, JY Henry, H Yagita, JD Wolchok, KS Peggs, JV Ravetch, JP Allison, SA Quezada (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210. 2013/07/31 edn.  https://doi.org/10.1084/jem.20130579
  142. 142.
    Y Bulliard, R Jolicoeur, M Windman, SM Rue, S Ettenberg, DA Knee, NS Wilson, G Dranoff, JL Brogdon (2013) activating fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210. 2013/07/31 edn.  https://doi.org/10.1084/jem.20130573
  143. 143.
    D Hirschhorn-Cymerman, GA Rizzuto, T Merghoub, AD Cohen, F Avogadri, AM Lesokhin, AD Weinberg, JD Wolchok, AN Houghton (2009) OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 206, 2009/05/06 edn.  https://doi.org/10.1084/jem.20082205
  144. 144.
    KS Voo, L Bover, ML Harline, LT Vien, V Facchinetti, K Arima, LW Kwak, YJ Liu (2013) Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol 191. 2013/09/10 edn.  https://doi.org/10.4049/jimmunol.1202752
  145. 145.
    Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H (2010) Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16.  https://doi.org/10.1158/1078-0432.CCR-09-3243
  146. 146.
    Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM (2014) PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res 74.  https://doi.org/10.1158/0008-5472.CAN-13-2908
  147. 147.
    Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, Gey A, Rotem-Yehudar R, Pere H, Tran T, Guerin CL, Chauvat A, Dransart E, Alanio C, Albert S, Barry B, Sandoval F, Quintin-Colonna F, Bruneval P, Fridman WH, Lemoine FM, Oudard S, Johannes L, Olive D, Brasnu D, Tartour E (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73.  https://doi.org/10.1158/0008-5472.CAN-12-2606
  148. 148.
    Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515.  https://doi.org/10.1038/nature13954
  149. 149.
    Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E (2017) Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO open 2.  https://doi.org/10.1136/esmoopen-2017-000213
  150. 150.
    Karaki S, Anson M, Tran T, Giusti D, Blanc C, Oudard S, Tartour E (2016) Is there still room for Cancer vaccines at the era of checkpoint inhibitors. Vaccines 4.  https://doi.org/10.3390/vaccines4040037
  151. 151.
    Y Hailemichael, AWoods, T Fu, Q He, MC Nielsen, F Hasan, J Roszik, Z Xiao, C Vianden, H Khong, M Singh, M Sharma, F Faak, D Moore, Z Dai, SM Anthony, KS Schluns, P Sharma, VH Engelhard, WW Overwijk (2018) Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. The J Clin Investig 128. 2018/02/27 edn.  https://doi.org/10.1172/JCI93303
  152. 152.
    JF Grosso, CC Kelleher, TJ Harris, CH Maris, EL Hipkiss, A De Marzo, R Anders, G Netto, D Getnet, TC Bruno, MV Goldberg, DM Pardoll, CG Drake (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumortolerance systems. J Clin Investig 117. 2007/10/13 edn.  https://doi.org/10.1172/JCI31184
  153. 153.
    Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M (2013) Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother 62.  https://doi.org/10.1007/s00262-012-1371-9
  154. 154.
    I Le Mercier, W Chen, JL Lines, M Day, J Li, P Sergent, RJ Noelle, L Wang (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res 74. 2014/04/03 edn.  https://doi.org/10.1158/0008-5472.CAN-13-1506
  155. 155.
    Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA (2015) Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A 112.  https://doi.org/10.1073/pnas.1514418112
  156. 156.
    AT den Boer, L Diehl, GJ van Mierlo, EI van der Voort, MF Fransen, P Krimpenfort, CJ Melief, R Offringa, RE Toes (2001) Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol 167Google Scholar
  157. 157.
    Carlring J, Szabo MJ, Dickinson R, De Leenheer E, Heath AW (2012) Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice. Blood 119.  https://doi.org/10.1182/blood-2011-05-355461
  158. 158.
    S Murata, BH Ladle, PS Kim, ER Lutz, ME Wolpoe, SE Ivie, HM Smith, TD Armstrong, LA Emens, EM Jaffee, RT Reilly (2006) OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 176Google Scholar
  159. 159.
    T De Smedt, J Smith, P Baum, W Fanslow, E Butz, C Maliszewski (2002) Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J Immunol 168Google Scholar
  160. 160.
    YC Lin, YT Chiu, YC Lin, JM Wu, CH Chen, WF Cheng, CM Wu (2018) Anti-OX-40 agonist antibody significantly increases therapeutic efficacy of TVGV-1 vaccine for HPV-positive cancers In: Annual meeting AACR, Chicago. Cancer ResGoogle Scholar
  161. 161.
    Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73.  https://doi.org/10.1158/0008-5472.CAN-12-4100
  162. 162.
    Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107.  https://doi.org/10.1073/pnas.0915174107
  163. 163.
    Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL (2016) Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci U S A 113.  https://doi.org/10.1073/pnas.1510518113
  164. 164.
    Sorensen MR, Holst PJ, Steffensen MA, Christensen JP, Thomsen AR (2010) Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 28.  https://doi.org/10.1016/j.vaccine.2010.07.066
  165. 165.
    Ito D, Ogasawara K, Matsushita K, Morohashi T, Namba K, Matsuki N, Kitaichi N, Inuyama Y, Hosokawa M, Nakayama E, Iwabuchi K, Onoe K (2000) Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies. Immunobiology 201.  https://doi.org/10.1016/S0171-2985(00)80072-8
  166. 166.
    Cho HI, Jung SH, Sohn HJ, Celis E, Kim TG (2015) An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects. Oncoimmunology 4.  https://doi.org/10.1080/2162402X.2015.1043504
  167. 167.
    AJ McGray, D Bernard, R Hallett, R Kelly, M Jha, C Gregory, JD Bassett, JA Hassell, G Pare, Y Wan, JL Bramson (2012) Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 1Google Scholar
  168. 168.
    HS Ma, E Torres, B Poudel, T Robinson, B Christmas, K Cruz, S Woolman, C Rafie, B Scott, V Wall, T Armstrong, E Jaffee (2018) Combination CD40 agonist and PD-1 antagonist antibody therapy enhances vaccine inducedT cell responses in non-immunogenic cancers In: AACR, Chicago. Cancer ResGoogle Scholar
  169. 169.
    Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, Roussel H, Mandavit M, Ravel P, Sibony M, Biard L, Radulescu C, Vinatier E, Benhamouda N, Peyromaure M, Oudard S, Mejean A, Timsit MO, Gey A, Tartour E (2017) Tim-3 expression on tumor-infiltrating PD-1+CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res 77.  https://doi.org/10.1158/0008-5472.CAN-16-0274
  170. 170.
    AA Sarnaik BY, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS (2011) Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected highrisk stage IIIc/IV melanoma. Clin Cancer Res 17.  https://doi.org/10.1158/1078-0432.CCR-10-2463
  171. 171.
    Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363.  https://doi.org/10.1056/NEJMoa1003466
  172. 172.
    P Attia, GQ Phan, AV Maker, MR Robinson, MM Quezado, JC Yang, RM Sherry, SL Topalian, US Kammula, RE Royal, NP Restifo, LR Haworth, C Levy, SA Mavroukakis, G Nichol, MJ Yellin, SA Rosenberg (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol 23Google Scholar
  173. 173.
    Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15.  https://doi.org/10.1158/1078-0432.CCR-09-1254
  174. 174.
    Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B (2016) Phase II study of autologous monocyte-derived mRNA Electroporated dendritic cells (TriMixDC-MEL) plus Ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 34.  https://doi.org/10.1200/JCO.2015.63.4121
  175. 175.
    Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL (2012) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13.  https://doi.org/10.1016/S1470-2045(12)70006-2
  176. 176.
    Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, HD Inzunza BY, Martinez AJ, Younos I, Weber JS (2015) Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21.  https://doi.org/10.1158/1078-0432.CCR-14-2468
  177. 177.
    J Nesselhut, D Marx, H Lange, G Regalo, N Cillien, RY Chang, T Nesselhut (2016) systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic Cancer In: ASCO Annual Meeting, Chicago, 2016. J Clin Oncol,Google Scholar
  178. 178.
    B Glisson, E Massarelli, WN William, FM Johnson, MS Kies, R Ferrarotto, M Guo, SA Peng, JJ Lee, H tran, YU Kim, C Haymaker, C Bernatchez, M Curran, B Sanchez Espiridion, JR Canales, II Wistuba, SH Van der Burg, J Wang, CJ Melief (2017) Nivolumab and ISA 101 HPV vaccine in incurable HPVSemin Immunopathol 16+ Cancer In: ESMO, Spain. Suppl 5. Ann Oncol, pp v493-V427Google Scholar
  179. 179.
    H Khong, AVolmari, M Sharma, Z Dai, CS Imo, Y Hailemichael, M Singh, DT Moore, Z Xiao, XF Huang, TD Horvath, DH Hawke, WW Overwijk (2018) Peptide vaccine formulation controls the duration of antigen presentation and magnitude of tumorspecific CD8(+) T cell response. J Immunol 200. 2018/04/13 edn.  https://doi.org/10.4049/jimmunol.1700467
  180. 180.
    B Vingert, O Adotevi, D Patin, S Jung, P Shrikant, L Freyburger, C Eppolito, A Sapoznikov, M Amessou, F Quintin-Colonna, WH Fridman, L Johannes, E Tartour (2006) The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 36Google Scholar
  181. 181.
    N Bercovici, N Haicheur, S Massicard, F Vernel-Pauillac, O Adotevi, D Landais, I Gorin, C Robert, HM Prince, JJ Grob, MT Leccia, T Lesimple, J Wijdenes, J Bartholeyns, WH Fridman, M Salcedo, E Ferries, E Tartour (2008) Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 31. 2007/12/25 EDN  https://doi.org/10.1097/CJI.0b013e318159f5ba
  182. 182.
    S Oudard, O Rixe, B Beuselinck, C Linassier, E Banu, JP Machiels, M Baudard, F Ringeisen, T Velu, MA Lefrere-Belda, JM Limacher, WH Fridman, M Azizi, B Acres, E Tartour (2011) A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 60 2010/11/12 edn.  https://doi.org/10.1007/s00262-010-0935-9
  183. 183.
    KD Moynihan, CF Opel, GL Szeto, A Tzeng, EF Zhu, JM Engreitz, RT Williams, K Rakhra, MH Zhang, AM Rothschilds, S Kumari, RL Kelly, BH Kwan, WAbraham, K Hu, NK Mehta, MJ Kauke, H Suh, JR Cochran, DA Lauffenburger, KD Wittrup, DJ Irvine (2016) Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 22. 2016/11/01 edn. doi:  https://doi.org/10.1038/nm.4200
  184. 184.
    Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN (2004) CTLA-4 blockade in combination with xenogeneic DNAvaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22.  https://doi.org/10.1016/j.vaccine.2003.10.048
  185. 185.
    RK Shrimali, S Ahmad, V Verma, P Zeng, S Ananth, P Gaur, RM Gittelman, E Yusko, C Sanders, H Robins, SA Hammond, JE Janik, M Mkrtichyan, S Gupta, SN Khleif (2017) Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol Res 5. 2017/08/30 edn.  https://doi.org/10.1158/2326-6066.CIR-17-0292
  186. 186.
    F Wang, E Bade, C Kuniyoshi, L Spears, G Jeffery, V Marty, S Groshen, J Weber (1999) Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 5. 1999/10/28 EDNGoogle Scholar
  187. 187.
    N Leffers, AJ Lambeck, MJ Gooden, BN Hoogeboom, R Wolf, IE Hamming, BG Hepkema, PH Willemse, BH Molmans, H Hollema, JW Drijfhout, WJ Sluiter, AR Valentijn, LM Fathers, J Oostendorp, AG van der Zee, CJ Melief, SH van der Burg, T Daemen, HW Nijman (2009) Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 125. 2009/07/22 edn.  https://doi.org/10.1002/ijc.24597
  188. 188.
    FM Speetjens, PJ Kuppen, MJ Welters, F Essahsah, AM Voet van den Brink, MG Lantrua, AR Valentijn, J Oostendorp, LM Fathers, HW Nijman, JW Drijfhout, CJ van de Velde, CJ Melief, SH van der Burg (2009) Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 15. 2009/02/04 edn.  https://doi.org/10.1158/1078-0432.CCR-08-2227
  189. 189.
    T Kimura, JR McKolanis, LA Dzubinski, K Islam, DM Potter, AM Salazar, RE Schoen, OJ Finn (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6. 2012/12/19 edn.  https://doi.org/10.1158/1940-6207.CAPR-12-0275

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • T. Tran
    • 1
    • 2
  • C. Blanc
    • 1
    • 2
  • C. Granier
    • 1
    • 2
  • A. Saldmann
    • 1
    • 2
  • C. Tanchot
    • 1
    • 2
  • Eric Tartour
    • 1
    • 2
    • 3
    • 4
  1. 1.INSERM U970, Paris Cardiovascular Research Center (PARCC)ParisFrance
  2. 2.Université Paris DescartesParisFrance
  3. 3.Hôpital Européen Georges Pompidou, Laboratory of ImmunologyAssistance Publique des Hôpitaux de ParisParisFrance
  4. 4.Equipe Labellisée Ligue Nationale contre le CancerParisFrance

Personalised recommendations